{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:13:37Z","timestamp":1790936017922,"version":"4.1.0"},"reference-count":23,"publisher":"American Society for Microbiology","issue":"9","license":[{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Clin Vaccine Immunol"],"published-print":{"date-parts":[[2010,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            A recombinant botulinum vaccine (rBV A\/B) is being developed for protection against inhalational intoxication with botulinum neurotoxin (BoNT) complex serotype A, subtype A1 (BoNT\/A1), and BoNT serotype B, subtype B1 (BoNT\/B1). A critical component for evaluating rBV A\/B efficacy will be the use of animal models in which the pathophysiology and dose-response relationships following aerosol exposure to well-characterized BoNT are thoroughly understood and documented. This study was designed to estimate inhaled 50% lethal doses (LD\n            <jats:sub>50<\/jats:sub>\n            ) and to estimate 50% lethal exposure concentrations relative to time (LCt\n            <jats:sub>50<\/jats:sub>\n            ) in rhesus macaques exposed to well-characterized BoNT\/A1 and BoNT\/B1. During the course of this study, clinical observations, body weights, clinical hematology results, clinical chemistry results, circulating neurotoxin levels, and telemetric parameters were documented to aid in the understanding of disease progression. The inhaled LD\n            <jats:sub>50<\/jats:sub>\n            and LCt\n            <jats:sub>50<\/jats:sub>\n            for BoNT\/A1 and BoNT\/B1 in rhesus macaques were determined using well-characterized challenge material. Clinical observations were consistent with the recognized pattern of botulism disease progression. A dose response was demonstrated with regard to the onset of these clinical signs for both BoNT\/A1 and BoNT\/B1. Dose-related changes in physiologic parameters measured by telemetry were also observed. In contrast, notable changes in body weight, hematology, and clinical chemistry parameters were not observed. Circulating levels of BoNT\/B1 were detected in animals exposed to the highest levels of BoNT\/B1; however, BoNT\/A1 was not detected in the circulation at any aerosol exposure level. The rhesus macaque aerosol challenge model will be used for future evaluations of rBV A\/B efficacy against inhalational BoNT\/A1 and BoNT\/B1 intoxication.\n          <\/jats:p>","DOI":"10.1128\/cvi.00080-10","type":"journal-article","created":{"date-parts":[[2010,7,22]],"date-time":"2010-07-22T02:20:00Z","timestamp":1279765200000},"page":"1293-1304","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":25,"title":["Inhalational Botulism in Rhesus Macaques Exposed to Botulinum Neurotoxin Complex Serotypes A1 and B1"],"prefix":"10.1128","volume":"17","author":[{"given":"Daniel C.","family":"Sanford","sequence":"first","affiliation":[{"name":"Battelle Biomedical Research Center, West Jefferson, Ohio"},{"name":"DynPort Vaccine Company LLC, Frederick, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy E.","family":"Barnewall","sequence":"additional","affiliation":[{"name":"Battelle Biomedical Research Center, West Jefferson, Ohio"},{"name":"DynPort Vaccine Company LLC, Frederick, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle L.","family":"Vassar","sequence":"additional","affiliation":[{"name":"Battelle Biomedical Research Center, West Jefferson, Ohio"},{"name":"DynPort Vaccine Company LLC, Frederick, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Niemuth","sequence":"additional","affiliation":[{"name":"Battelle Biomedical Research Center, West Jefferson, Ohio"},{"name":"DynPort Vaccine Company LLC, Frederick, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Metcalfe","sequence":"additional","affiliation":[{"name":"Battelle Biomedical Research Center, West Jefferson, Ohio"},{"name":"DynPort Vaccine Company LLC, Frederick, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert V.","family":"House","sequence":"additional","affiliation":[{"name":"Battelle Biomedical Research Center, West Jefferson, Ohio"},{"name":"DynPort Vaccine Company LLC, Frederick, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Henderson","sequence":"additional","affiliation":[{"name":"Battelle Biomedical Research Center, West Jefferson, Ohio"},{"name":"DynPort Vaccine Company LLC, Frederick, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffry D.","family":"Shearer","sequence":"additional","affiliation":[{"name":"Battelle Biomedical Research Center, West Jefferson, Ohio"},{"name":"DynPort Vaccine Company LLC, Frederick, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1046\/j.1468-1331.2001.00035.x","volume":"8","year":"2001","unstructured":"Aoki, K., and B. Guyer. 2001. Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions. Eur. J. Neurol.8(Suppl. 5):21-29.","journal-title":"Eur. J. Neurol."},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1001\/jama.285.8.1059","volume":"285","year":"2001","unstructured":"Arnon, S. S., R. Schechter, T. V. Inglesby, D. A. Henderson, J. G. Bartlett, M. S. Ascher, E. Eitzen, A. D. Fine, J. Hauer, M. Layton, S. Lillibridge, M. T. Osterholm, T. O'Toole, G. Parker, T. M. Perl, P. K. Russell, D. L. Swerdlow, and K. Tonat. 2001. Botulinum toxin as a biological weapon: medical and public health management. JAMA285:1059-1070.","journal-title":"JAMA"},{"key":"e_1_3_2_4_2","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1023\/B:VERC.0000048489.45634.32","volume":"29","year":"2005","unstructured":"B\u00f6hnel, H., and F. Gessler. 2005. Botulinum toxins\u2014cause of botulism and systemic diseases? Vet. Res. Commun.29:313-345.","journal-title":"Vet. Res. Commun."},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.toxicon.2006.02.013","volume":"47","year":"2006","unstructured":"Boles, J., M. West, V. Montgomery, R. Tammariello, M. L. Pitt, P. Gibbs, L. A Smith, and R. D. LeClaire. 2006. Recombinant C fragment of botulinum neurotoxin B serotype (rBoNTB (Hc)) immune response and protection in the rhesus monkey. Toxicon47:877-884.","journal-title":"Toxicon"},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0300-9084(00)01173-1","volume":"82","year":"2000","unstructured":"Byrne, M., and L. A. Smith. 2000. Development of vaccines for prevention of botulism. Biochimie82:955-966.","journal-title":"Biochimie"},{"key":"e_1_3_2_7_2","unstructured":"Food and Drug Administration Department of Health and Human Services 2009"},{"key":"e_1_3_2_8_2","unstructured":"Botulism in the United States 1899-1996: handbook for epidemiologists clinicians and laboratory workers. 1998"},{"key":"e_1_3_2_9_2","unstructured":"Emergency Preparedness and Response Bioterrorism. 2010"},{"key":"e_1_3_2_10_2","unstructured":"Botulism. Centers for Disease Control and Prevention 2010"},{"key":"e_1_3_2_11_2","unstructured":"Code of Federal Regulations 2009 vol. 7"},{"key":"e_1_3_2_12_2","first-page":"37","year":"1992","unstructured":"Feder, P. I., D. W. Hobson, C. T. Olson, R. L. Joiner, and M. C. Matthews. 1992. Statistical design considerations for stagewise, adaptive dose allocation in dose-response studies, p. 37-86. In K. E. Peace (ed.), Biopharmaceutical sequential statistical applications. Marcel Dekker, New York, NY.","journal-title":"Biopharmaceutical sequential statistical applications."},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1177\/009286159102500304","volume":"25","year":"1991","unstructured":"Feder, P. I., C. T. Olson, D. W. Hobson, M. C. Matthews, and R. L. Joiner. 1991. Statistical analysis of dose-response experiments by maximum likelihood analysis and iteratively reweighted nonlinear least squares regression techniques. Drug Inf. J.25:323-334.","journal-title":"Drug Inf. J."},{"key":"e_1_3_2_14_2","unstructured":"Probit analysis 1971"},{"key":"e_1_3_2_15_2","first-page":"473","year":"1993","unstructured":"Franz, D. R., L. M. Pitt, M. A. Clayton, M. A. Hanes, and K. J. Rose. 1993. Efficacy of prophylactic and therapeutic administration of antitoxin for inhalation botulism, p. 473-476. In B. R. DasGupta (ed.), Botulism and tetanus neurotoxins: neurotransmission and biomedical aspects. Plenum Press, New York, NY.","journal-title":"Botulism and tetanus neurotoxins: neurotransmission and biomedical aspects"},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/0014-4800(67)90007-X","volume":"6","year":"1967","unstructured":"Herrero, B. A., A. E. Ecklung, C. S. Streett, D. F. Ford, and J. K. King. 1967. Experimental botulism in monkeys: a clinical pathology study. Exp. Mol. Pathol.6:84-95.","journal-title":"Exp. Mol. Pathol."},{"key":"e_1_3_2_17_2","first-page":"54","year":"2005","unstructured":"LeClaire, R. D., and L. M. Pitt. 2005. Agent effect levels, p. 54. In L. E. Lindler, F. J. Lebeda, and G. Korch (ed.), Biological weapons defense: infectious disease and counterbioterrorism. Humana Press, Totowa, NJ.","journal-title":"Biological weapons defense: infectious disease and counterbioterrorism"},{"key":"e_1_3_2_18_2","unstructured":"Pathophysiology: the biologic basis for disease in adults and children 2002"},{"key":"e_1_3_2_19_2","unstructured":"National Research Council. 1996. Guide for the care and use of laboratory animals. National Academy Press Washington DC."},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/mds.870030409","volume":"3","year":"1988","unstructured":"Scott, A. B., and D. Suzuki. 1988. Systemic toxicity of botulinum toxin by intramuscular injection in the monkey. Mov. Disord.3:333-335.","journal-title":"Mov. Disord."},{"key":"e_1_3_2_21_2","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1146\/annurev.pharmtox.44.101802.121554","volume":"44","year":"2004","unstructured":"Simpson, L. L. 2004. Identification of the major steps in botulinum toxin action. Annu. Rev. Pharmacol. Toxicol.44:167-193.","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"e_1_3_2_22_2","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1615\/CritRevImmunol.v27.i4.20","volume":"27","year":"2007","unstructured":"Smith, L. A., and J. M. Rusnak. 2007. Botulinum neurotoxin vaccines: past, present, and future. Crit. Rev. Immunol.27:303-318.","journal-title":"Crit. Rev. Immunol."},{"key":"e_1_3_2_23_2","doi-asserted-by":"crossref","first-page":"D33","DOI":"10.1016\/j.vaccine.2009.08.059","volume":"27","year":"2009","unstructured":"Smith, L. A. 2009. Botulism and vaccines for its prevention. Vaccine27:D33-D39.","journal-title":"Vaccine"},{"key":"e_1_3_2_24_2","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1086\/444507","volume":"41","year":"2005","unstructured":"Sobel, J. 2005. Botulism. Clin. Infect. Dis.41:1167-1173.","journal-title":"Clin. Infect. Dis."}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00080-10","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00080-10","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T20:44:06Z","timestamp":1627591446000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.00080-10"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["10.1128\/CVI.00080-10"],"URL":"https:\/\/doi.org\/10.1128\/cvi.00080-10","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9]]},"assertion":[{"value":"2010-02-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2010-07-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}